News and Updates
eMediNexus Coverage from: 
FDA approves Dupixent for atopic dermatitis in teenagers
eMediNexus,  13 March 2019
remove_red_eye 530 Views
#Allergy and Immunology #Dermatology #Pediatrics #Pharmacist

0 Read Comments                

The FDA has expanded the approval of dupilumab (Dupixent) to include treatment of moderate-to-severe atopic dermatitis in patients ages 12 to 17. Dupilumab, which was already approved for atopic dermatitis in adults, can be used with or without topical corticosteroids.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now